Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Uterine Corpus Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
31 drugs · 147 active trials
4 drugs · 55 active trials
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab | Approved | Phase 3 | 36 | 21 | 8 | 59 | 3 | US | Sep 4, 2014 | Jul 17, 2014 |
| Dostarlimab | Approved | Phase 3 | 8 | 3 | 1 | 9 | 2 | EU, US | Apr 21, 2021 | Nov 6, 2017 |
| Lenvatinib | Approved | Phase 3 | 7 | 3 | 1 | 11 | 1 | US | Feb 13, 2015 | 2010-03 |
| Durvalumab | Approved | Phase 3 | 4 | 2 | 1 | 8 | 1 | US | May 1, 2017 | Jun 3, 2016 |
| Letrozole | Phase 4 | Phase 4 | 9 | 6 | 2 | 19 | 0 | — | — | Jan 19, 2000 |
| Aspirin | Phase 4 | Phase 4 | 1 | 0 | 0 | 2 | 0 | — | — | Jul 1, 2017 |
| Sirolimus | Phase 4 | Phase 4 | 0 | 0 | 0 | 2 | 0 | — | — | 2012-03 |
| Goserelin | Phase 4 | Phase 4 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-01 |
| Paclitaxel | Phase 3 | Phase 3 | 32 | 18 | 30 | 91 | 0 | — | — | 1996-07 |
| Carboplatin | Phase 3 | Phase 3 | 23 | 13 | 18 | 69 | 0 | — | — | 1998-02 |
| Cisplatin | Phase 3 | Phase 3 | 15 | 9 | 21 | 56 | 0 | — | — | 1992-05 |
| Bevacizumab | Phase 3 | Phase 3 | 15 | 12 | 3 | 32 | 0 | — | — | 2006-03 |
| Doxorubicin | Phase 3 | Phase 3 | 11 | 7 | 16 | 33 | 0 | — | — | 1992-05 |
| Megestrol | Phase 3 | Phase 3 | 7 | 4 | 4 | 17 | 0 | — | — | 1987-12 |
| Olaparib | Phase 3 | Phase 3 | 7 | 3 | 2 | 13 | 0 | — | — | Feb 7, 2011 |
| Gemcitabine | Phase 3 | Phase 3 | 4 | 2 | 3 | 21 | 0 | — | — | 1999-07 |
| Niraparib | Phase 3 | Phase 3 | 4 | 2 | 2 | 11 | 0 | — | — | Aug 29, 2017 |
| Atezolizumab | Phase 3 | Phase 3 | 4 | 2 | 1 | 8 | 0 | — | — | Mar 10, 2017 |
| Docetaxel | Phase 3 | Phase 3 | 3 | 3 | 5 | 20 | 0 | — | — | 1998-05 |
| Metformin | Phase 3 | Phase 3 | 3 | 1 | 2 | 16 | 0 | — | — | 2008-03 |
| Chemotherapy | Phase 3 | Phase 3 | 3 | 2 | 3 | 4 | 0 | — | — | 2008-08 |
| Sacituzumab Govitecan | Phase 3 | Phase 3 | 3 | 1 | 1 | 4 | 0 | — | — | Dec 17, 2012 |
| Selinexor | Phase 3 | Phase 3 | 2 | 0 | 2 | 6 | 0 | — | — | Apr 9, 2014 |
| Nab-paclitaxel | Phase 3 | Phase 3 | 2 | 1 | 1 | 5 | 0 | — | — | 2006-11 |
| Carboplatin/Paclitaxel Regimen | Phase 3 | Phase 3 | 2 | 1 | 2 | 4 | 0 | — | — | 2011-06 |
| Fruquintinib | Phase 3 | Phase 3 | 2 | 1 | 1 | 3 | 0 | — | — | Aug 9, 2021 |
| Topotecan | Phase 3 | Phase 3 | 1 | 0 | 3 | 9 | 0 | — | — | 2003-05 |
| Relugolix | Phase 3 | Phase 3 | 1 | 1 | 7 | 8 | 0 | — | — | 2011-10 |
| Ifosfamide | Phase 3 | Phase 3 | 1 | 1 | 3 | 4 | 0 | — | — | 1995-02 |
| Sintilimab | Phase 3 | Phase 3 | 1 | 1 | 1 | 2 | 0 | — | — | Jul 1, 2022 |
| Navtemadlin | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Jul 17, 2023 |
| Filgrastim | Phase 3 | Phase 3 | 0 | 0 | 8 | 12 | 0 | — | — | 1995-02 |
| Pegfilgrastim | Phase 3 | Phase 3 | 0 | 0 | 4 | 7 | 0 | — | — | 2000-07 |
| Leuprolide | Phase 3 | Phase 3 | 0 | 0 | 3 | 5 | 0 | — | — | 2006-06 |
| Tamoxifen | Phase 3 | Phase 3 | 0 | 0 | 2 | 3 | 0 | — | — | 1997-03 |
| Vinorelbine | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 1996-07 |
| Dactinomycin | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 1999-06 |
| Epirubicin | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2000-01 |
| Methotrexate | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 1999-06 |
| Abemaciclib | Phase 2 | Phase 2 | 9 | 6 | 0 | 12 | 0 | — | — | Aug 21, 2018 |
| Nivolumab | Phase 2 | Phase 2 | 8 | 3 | 0 | 13 | 0 | — | — | May 18, 2015 |
| Everolimus | Phase 2 | Phase 2 | 5 | 0 | 0 | 9 | 0 | — | — | 2004-06 |
| Fulvestrant | Phase 2 | Phase 2 | 4 | 3 | 0 | 11 | 0 | — | — | 2002-12 |
| Cabozantinib | Phase 2 | Phase 2 | 4 | 1 | 0 | 6 | 0 | — | — | May 8, 2013 |
| Capivasertib | Phase 2 | Phase 2 | 4 | 1 | 0 | 5 | 0 | — | — | Dec 1, 2010 |
| Ipatasertib | Phase 2 | Phase 2 | 4 | 2 | 0 | 4 | 0 | — | — | Aug 17, 2015 |
| Trastuzumab | Phase 2 | Phase 2 | 3 | 1 | 0 | 7 | 0 | — | — | Sep 18, 2000 |
| Fluorouracil | Phase 2 | Phase 2 | 3 | 3 | 0 | 6 | 0 | — | — | 1997-11 |
| Irinotecan | Phase 2 | Phase 2 | 3 | 3 | 0 | 5 | 0 | — | — | 2001-12 |
| Palbociclib | Phase 2 | Phase 2 | 3 | 2 | 0 | 4 | 0 | — | — | Aug 17, 2015 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.